Mumbai: Aurobindo Pharma Ltd has received approval from the US Food & Drug Administration to market its 300mg Cefdinir capsules in the US market.
The drug falls under the anti-bacterial segment and is a generic equivalent of Abbott Laboratories, 'OMNICEF'.
Earlier, the company also received the final approval for 125 mg/5 ml and 250 mg/5 ml oral suspension of this drug from the USFDA.
• Check out our Yearender Special
This is Aurobindo's 62nd ANDA approval from USFDA.
